Epicriptine
|  | |
| Clinical data | |
|---|---|
| Other names | beta-Dihydroergocryptine | 
| Pregnancy category | 
 | 
| Routes of administration | Oral | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.039.157 | 
| Chemical and physical data | |
| Formula | C32H43N5O5 | 
| Molar mass | 577.726 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Epicriptine or beta-dihydroergocryptine is a dopamine agonist of the ergoline class. It constitutes one third of the mixture known as dihydroergocryptine, the other two thirds consisting of alpha-dihydroergocryptine. The alpha differs from the beta form only in the position of a single methyl group, which is a consequence of the biosynthesis in which the proteinogenic amino acid isoleucine is replaced by leucine.[1]
References